SGO2: A Protein Target for Cancer and Neurodegenerative Diseases

Target Name: SGO2

NCBI ID: G151246

SGO2

SGO2: A Protein Target for Cancer and Neurodegenerative Diseases

SGO2 (Tripin) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and blood vessels. It is a member of the Integrin receptor family, which is involved in cell-cell and cell-matrix interactions. SGO2 plays a role in the development and maintenance of blood vessels, as well as in the regulation of cell growth and differentiation.

SGO2 has also been shown to be involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to the development of SGO2 as a potential drug target.

One of the key challenges in studying SGO2 is its complex structure. SGO2 is a transmembrane protein that is composed of an extracellular region, a transmembrane region, and an intracellular region. The transmembrane region is the region that is involved in the protein's function, as it is involved in the regulation of cell-cell and cell-matrix interactions.

The structure of SGO2 has been determined through various techniques, including X-ray crystallography and biochemical studies. These studies have provided insight into the three-dimensional structure of SGO2 and have led to the development of models to predict its function.

One of the key features of SGO2 is its ability to interact with other proteins. SGO2 has been shown to interact with several proteins, including the protein tyrosine phosphatase (PTP) and the protein src. These interactions are important for the regulation of SGO2 function and are the target of several potential drug compounds.

In addition to its role in cell-cell and cell-matrix interactions, SGO2 is also involved in the regulation of cell growth and differentiation. This is accomplished through its role in the Wnt signaling pathway, a pathway that is involved in the regulation of cell growth and differentiation.

SGO2 has also been shown to be involved in the regulation of angiogenesis, the process by which new blood vessels are formed. This is accomplished through its role in the production of vascular endothelial growth factor (VEGF), a protein that is involved in the regulation of angiogenesis.

In conclusion, SGO2 is a protein that is involved in a number of important processes in the body. Its role in the regulation of blood vessels, cell growth and differentiation, and angiogenesis makes it a potential drug target. Further research is needed to fully understand the function of SGO2 and its potential as a drug.

Protein Name: Shugoshin 2

Functions: Cooperates with PPP2CA to protect centromeric cohesin from separase-mediated cleavage in oocytes specifically during meiosis I. Has a crucial role in protecting REC8 at centromeres from cleavage by separase. During meiosis, protects centromeric cohesion complexes until metaphase II/anaphase II transition, preventing premature release of meiosis-specific REC8 cohesin complexes from anaphase I centromeres. Is thus essential for an accurate gametogenesis. May act by targeting PPP2CA to centromeres, thus leading to cohesin dephosphorylation (By similarity). Essential for recruiting KIF2C to the inner centromere and for correcting defective kinetochore attachments. Involved in centromeric enrichment of AUKRB in prometaphase

The "SGO2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SGO2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets